Epstein-Barr virus reactivation in renal transplant recipients
MetadataShow full item record
Please cite this item using this persistent URLhttp://hdl.handle.net/10019.1/7947
This item appears in the following collection/s
- BB - Editors 
Renal transplant recipients at Tygerberg Hospital were investigated to determine the importance of Epstein-Barr virus (EBV) as a pathogen in these patients. All 106 patients investigated were shown to have EBV antibodies before transplantation and most had serological evidence of reactivation of the infection after transplantation. A mild clinical illness was present in a few patients concomitant with EBV reactivation, which may suggest that this virus has a role in the morbidity of some renal transplant recipients. Lymphoblastoid cell lines were established from 11 renal transplant recipients; 5 of these cell lines were shown to be virus producers and 1 is thought to have unique properties.
Showing items related by title, author, creator and subject.
Ijpma, F. F. A.; Beekhuis, D.; Cotton, M. F.; Pieper, C. H.; Kimpen, J. L. L.; Van Den Hoogen, B. G.; Van Doornum, G. J. J.; Osterhaus, D. M. E. (2004)Human metapneumovirus (hMPV) was first described in Dutch children with acute respiratory symptoms. A prospective analysis of the epidemiology, clinical manifestation, and seroprevalence of hMPV and other respiratory viruses ...
Smith, T.L.; Van Rensburg, E. J.; Engelbrecht, S. (1998)More than 20.8 million people are infected with HIV in sub-Saharan Africa, with South Africa having one of the fastest growing HIV-1 epidemics, where an estimated 2.4 million people were infected. Thirty-two sera from 25 ...
Evaluation of envelope vaccines derived from the South African subtype C human immunodeficiency virus type 1 TV1 strain Lian Y.; Srivastava I.; Gomez-Roman V.R.; Zur Megede J.; Sun Y.; Kan E.; Hilt S.; Engelbrecht S.; Himathongkham S.; Luciw P.A.; Otten G.; Ulmer J.B.; Donnelly J.J.; Rabussay D.; Montefiori D.; Van Rensburg E.J.; Barnett S.W. (2005)Human immunodeficiency virus type 1 (HIV-1) subtype C infections are on the rise in Sub-Saharan Africa and Asia. Therefore, there is a need to develop an HIV vaccine capable of eliciting broadly reactive immune responses ...